Nitazenes and Medetomidine Update (2025-2026 Recording)-Nitazenes and Medetomidine Update

Video Transcription

Video Summary

Dr. Ed Salsitz discussed emerging illicit synthetic drugs, focusing on nitazines and metatomidine/xylosine. He explained that nitazines are highly potent benzimidazole opioids, originally developed decades ago but never marketed because of dangerous respiratory depression. Recently, they have appeared in counterfeit pills, heroin, fentanyl, and other street drugs in the U.S., Europe, Canada, and elsewhere. Their potency can exceed fentanyl by many times, and their active metabolites may be even stronger. Because routine toxicology often misses them, nitazine-related overdoses are likely undercounted. Naloxone still works, but higher and repeated doses may be needed, and many cases require hospitalization.<br /><br />He also reviewed brophine, another potent synthetic opioid linked to “purple heroin” outbreaks.<br /><br />In the second half, he turned to xylosine and the newer veterinary sedative metatomidine, describing them as alpha-2 agonists that can worsen opioid overdoses and cause prolonged sedation, bradycardia, and severe withdrawal. Metatomidine appears to be a more potent successor to xylosine, fitting the “iron law of prohibition,” where supply pressure on one drug leads to even more potent substitutes. He emphasized aggressive treatment strategies, including naloxone, methadone, clonidine, and ICU-level care when needed.

Keywords

nitazines

synthetic opioids

benzimidazole opioids

fentanyl adulteration

naloxone

xylosine

metatomidine

opioid overdose